Browse by UCL Departments and Centres
![[up]](/style/images/multi_up.png)
Up a levelGroup by: Author | Type
Number of items: 55.
Article
Barrington, SF;
Phillips, EH;
Counsell, N;
Hancock, B;
Pettengell, R;
Johnson, P;
Townsend, W;
... Radford, J; + view all
(2019)
Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study.
Journal of Clinical Oncology
, 37
(20)
pp. 1732-1741.
10.1200/JCO.18.01799.
|
 |
|
Barrington, SF;
Phillips, EH;
Counsell, N;
Radford, J;
(2019)
Reply to H.J.A. Adams et al and C. Kobe et al.
Journal of Clinical Oncology
, 37
(34)
pp. 3325-3326.
10.1200/JCO.19.02056.
|
|
Barton, J;
Pacey, K;
Jain, N;
Kasia, T;
Edwards, D;
Thevanesan, C;
Straathof, K;
... Anderson, J; + view all
(2019)
Establishment and phenotyping of neurosphere cultures from primary neuroblastoma samples.
F1000Research
, 8
, Article 823. 10.12688/f1000research.18209.1.
|
|
|
Biswas, D;
Birkbak, NJ;
Rosenthal, R;
Hiley, CT;
Lim, EL;
Papp, K;
Boeing, S;
... TRACERx Consortium; + view all
(2019)
A clonal expression biomarker associates with lung cancer mortality.
Nature Medicine
, 25
pp. 1540-1548.
10.1038/s41591-019-0595-z.
|
|
Bray, TJP;
Lopes, A;
Fisher, C;
Ciurtin, C;
Sen, D;
Hall-Craggs, MA;
(2019)
Sacroiliac Joint Ankylosis In Young Spondyloarthritis Patients Receiving Biologic Therapy: Observation of Serial MRI scans.
Arthritis and Rheumatology
, 71
(4)
pp. 594-598.
10.1002/art.40750.
|
|
Brown, P;
Tan, A-C;
El-Esawi, MA;
Liehr, T;
Blanck, O;
Gladue, DP;
Almeida, GMF;
... Shalchyan, V; + view all
(2019)
Large expert-curated database for benchmarking document similarity detection in biomedical literature search.
Database
pp. 1-66.
10.1093/database/baz085.
|
|
Burt, R;
Dey, A;
Aref, S;
Aguiar, M;
Akarca, A;
Bailey, K;
Day, W;
... Fielding, AK; + view all
(2019)
Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress.
Blood
, 134
(17)
pp. 1415-1429.
10.1182/blood.2019001398.
|
|
Chavda, SJ;
Maciocia, PM;
Mesiri, P;
Counsell, N;
Kothari, J;
Bird, A;
Mariner, C;
... Yong, K; + view all
(2019)
A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1.
British Journal of Haematology
, 185
(2)
pp. 350-353.
10.1111/bjh.15487.
|
|
Chemi, F;
Rothwell, DG;
McGranahan, N;
Gulati, S;
Abbosh, C;
Pearce, SP;
Zhou, C;
... TRACERx Consortium, .; + view all
(2019)
Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse.
Nature Medicine
, 25
pp. 1534-1539.
10.1038/s41591-019-0593-1.
|
|
Clamp, AR;
James, EC;
McNeish, IA;
Dean, A;
Kim, J-W;
O'Donnell, DM;
Hook, J;
... Ledermann, JA; + view all
(2019)
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
The Lancet
10.1016/s0140-6736(19)32259-7.
|
|
|
Cohen, OC;
Counsell, N;
Rabin, N;
Popat, R;
Owen, RG;
Popova, B;
Schofield, O;
... Yong, KL; + view all
(2019)
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
[Letter].
British Journal of Haematology
, 185
(5)
pp. 948-951.
10.1111/bjh.15649.
|
|
Coleman, RL;
Ledermann, JA;
(2019)
Maintenance treatment for recurrent ovarian carcinoma – Evidence supporting the efficacy and safety of PARP inhibitors.
[Review].
European Oncology and Haematology
, 15
(1)
pp. 29-40.
10.17925/EOH.2019.15.1.29.
|
|
Colombo, N;
Sessa, C;
du Bois, A;
Ledermann, J;
McCluggage, WG;
McNeish, I;
Morice, P;
... Zeimet, AG; + view all
(2019)
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
International Journal of Gynecological Cancer
, 29
(4)
pp. 728-760.
10.1136/ijgc-2019-000308.
|
|
|
Colombo, N;
Sessa, C;
du Bois, A;
Ledermann, J;
McCluggage, WG;
McNeish, I;
Morice, P;
... ESMO–ESGO Ovarian Cancer Consensus Conference Working Group, .; + view all
(2019)
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.
Annals of Oncology
, 30
(5)
pp. 672-705.
10.1093/annonc/mdz062.
|
|
Coosemans, A;
Vankerckhoven, A;
Baert, T;
Boon, L;
Ruts, H;
Riva, M;
Blagden, S;
... Vergote, I; + view all
(2019)
Combining conventional therapy with immunotherapy: A risky business?
European Journal of Cancer
, 113
pp. 41-44.
10.1016/j.ejca.2019.02.014.
|
 |
|
Das-Gupta, E;
Thomson, KJ;
Bloor, AJC;
Clark, AD;
Mackinnon, S;
Kayani, I;
Clifton-Hadley, L;
... Peggs, KS; + view all
(2019)
Allo-HSCT in transplant-naive patients with Hodgkin lymphoma: a single-arm, multicenter study.
Blood Advances
, 3
(24)
pp. 4264-4270.
10.1182/bloodadvances.2019001016.
|
|
de Boer, SM;
Powell, ME;
Mileshkin, L;
Katsaros, D;
Bessette, P;
Haie-Meder, C;
Ottevanger, PB;
... Tubiana-Mathieu, N; + view all
(2019)
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
The Lancet Oncology
10.1016/S1470-2045(19)30395-X.
(In press).
|
|
|
Dehbi, H-M;
Mallick, U;
Wadsley, J;
Newbold, K;
Harmer, C;
Hackshaw, A;
(2019)
Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
Lancet Diabetes and Endocrinology
, 7
(1)
pp. 44-51.
10.1016/S2213-8587(18)30306-1.
|
|
|
Embleton-Thirsk, A;
Deane, E;
Townsend, S;
Farrelly, L;
Popoola, B;
Parker, J;
Rustin, G;
... Kaplan, R; + view all
(2019)
Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application.
Clinical Trials
, 16
(5)
pp. 502-511.
10.1177/1740774519862528.
|
|
|
Eyre, TA;
Kirkwood, AA;
Gohill, S;
Follows, G;
Walewska, R;
Walter, H;
Cross, M;
... the UK CLL Forum; + view all
(2019)
Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.
British Journal of Haematology
, 185
(4)
pp. 656-669.
10.1111/bjh.15802.
|
|
Eyre, TA;
Kirkwood, AA;
Wolf, J;
Hildyard, C;
Mercer, C;
Plaschkes, H;
Griffith, J;
... Hatton, CSR; + view all
(2019)
Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.
British Journal of Haematology
, 187
(2)
pp. 185-194.
10.1111/bjh.16070.
|
|
|
Ghorashian, S;
Kramer, AM;
Onuoha, S;
Wright, G;
Bartram, J;
Richardson, R;
Albon, SJ;
... Amrolia, PJ; + view all
(2019)
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR.
Nature Medicine
, 25
pp. 1408-1414.
10.1038/s41591-019-0549-5.
|
|
González Martín, A;
Oza, A;
Embleton, AC;
Pfisterer, J;
Ledermann, J;
Pujade-Lauraine, E;
Kristensen, G;
... Perren, T; + view all
(2019)
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.
Gynecologic Oncology
, 152
(1)
10.1016/j.ygyno.2018.08.036.
|
|
|
Gore, M;
Hackshaw, A;
Brady, WE;
Penson, RT;
Zaino, R;
McCluggage, WG;
Ganesan, R;
... Gershenson, DM; + view all
(2019)
An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
Gynecologic Oncology
, 153
(3)
pp. 541-548.
10.1016/j.ygyno.2019.03.256.
|
|
|
Gourley, C;
Balmaña, J;
Ledermann, JA;
Serra, V;
Dent, R;
Loibl, S;
Pujade-Lauraine, E;
(2019)
Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
Journal of Clinical Oncology
, 37
(25)
pp. 2257-2269.
10.1200/JCO.18.02050.
|
|
Hoskin, PJ;
Hopkins, K;
Misra, V;
Holt, T;
McMenemin, R;
Dubois, D;
McKinna, F;
... Lopes, A; + view all
(2019)
Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial.
JAMA
, 322
(21)
pp. 2084-2094.
10.1001/jama.2019.17913.
|
|
Hutchison, IL;
Ridout, F;
Cheung, SMY;
Shah, N;
Hardee, P;
Surwald, C;
Thiruchelvam, J;
... Hackshaw, A; + view all
(2019)
Nationwide randomised trial evaluating elective neck dissection for early stage oral cancer (SEND study) with meta-analysis and concurrent real-world cohort.
British Journal of Cancer
10.1038/s41416-019-0587-2.
(In press).
|
|
|
Joshi, K;
Robert de Massy, M;
Ismail, M;
Reading, JL;
Uddin, I;
Woolston, A;
Hatipoglu, E;
... Chain, B; + view all
(2019)
Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer.
Nature Medicine
, 25
pp. 1549-1559.
10.1038/s41591-019-0592-2.
|
|
Kristeleit, RS;
Oaknin, A;
Ray-Coquard, I;
Leary, A;
Balmaña, J;
Drew, Y;
Oza, AM;
... McNeish, IA; + view all
(2019)
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.
International Journal of Gynecological Cancer
, 29
(9)
pp. 1396-1404.
10.1136/ijgc-2019-000623.
|
|
|
Latifoltojar, A;
Punwani, S;
Lopes, A;
Humphries, PD;
Klusmann, M;
Menezes, LJ;
Daw, S;
... Taylor, SA; + view all
(2019)
Whole-body MRI for staging and interim response monitoring
in paediatric and adolescent Hodgkin's lymphoma: a comparison
with multi-modality reference standard including 18F-FDG-PET-CT.
European Radiology
, 29
(1)
pp. 202-212.
10.1007/s00330-018-5445-8.
|
|
|
Ledermann, JA;
(2019)
Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?
[Editorial comment].
Gynecologic Oncology
, 153
(2)
pp. 213-214.
10.1016/j.ygyno.2019.04.014.
|
|
Ledermann, JA;
(2019)
Extending the scope of PARP inhibitors in ovarian cancer.
[Editorial comment].
The Lancet Oncology
, 20
(4)
pp. 470-472.
10.1016/S1470-2045(19)30019-1.
|
|
Ledermann, JA;
Pujade-Lauraine, E;
(2019)
Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer.
Therapeutic Advances in Medical Oncology
, 11
pp. 1-18.
10.1177/1758835919849753.
|
|
|
Lee, SM;
Upadhyay, S;
Lewanski, C;
Falk, S;
Skailes, G;
Woll, PJ;
Hatton, M;
... Hackshaw, A; + view all
(2019)
The clinical role of VeriStrat testing in patients with advanced non-small cell lung cancer considered unfit for first-line platinum-based chemotherapy.
European Journal of Cancer
, 120
pp. 86-96.
10.1016/j.ejca.2019.07.025.
|
|
|
Mato, AR;
Roeker, LE;
Eyre, TA;
Nabhan, C;
Lamanna, N;
Hill, BT;
Brander, DM;
... Fox, CP; + view all
(2019)
A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.
Blood Advances
, 3
(10)
pp. 1568-1573.
10.1182/bloodadvances.2019000180.
|
|
|
Matulonis, UA;
Shapira-Frommer, R;
Santin, AD;
Lisyanskaya, AS;
Pignata, S;
Vergote, I;
Raspagliesi, F;
... Ledermann, JA; + view all
(2019)
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.
Annals of Oncology
, 30
(7)
pp. 1080-1087.
10.1093/annonc/mdz135.
|
|
Matulonis, UA;
Walder, L;
Nøttrup, TJ;
Bessette, P;
Mahner, S;
Gil-Martin, M;
Kalbacher, E;
... Mirza, MR; + view all
(2019)
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
Journal of Clinical Oncology
, 37
(34)
pp. 3183-3191.
10.1200/JCO.19.00917.
|
|
|
Miller, RE;
Crusz, SM;
Ledermann, JA;
(2019)
Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?
Future Oncology
, 15
(16)
pp. 1845-1853.
10.2217/fon-2019-0057.
|
|
Newton, C;
Murali, K;
Ahmad, A;
Hockings, H;
Graham, R;
Liberale, V;
Sarker, S-J;
... Lockley, M; + view all
(2019)
A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice.
European Journal of Cancer
, 113
pp. 19-27.
10.1016/j.ejca.2019.03.001.
|
|
|
O'Reilly, MA;
Govender, D;
Kirkwood, AA;
Vora, A;
Samarasinghe, S;
Khwaja, A;
Grandage, V;
... O'Connor, D; + view all
(2019)
The incidence of invasive fungal infections in children, adolescents and young adults with acute lymphoblastic leukaemia/lymphoma treated with the UKALL2011 protocol: a multicentre retrospective study.
[Letter].
British Journal of Haematology
, 186
(2)
pp. 327-329.
10.1111/bjh.15798.
|
|
Phillips, EH;
Lannon, M;
Lopes, A;
Chadwick, H;
Jones, G;
Sieniawski, M;
Davies, A;
... Lennard, A; + view all
(2019)
High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II Study.
[Letter].
Bone Marrow Transplantation
, 54
pp. 465-468.
10.1038/s41409-018-0294-2.
|
|
Rahman, B;
Lanceley, A;
Kristeleit, R;
Ledermann, J;
Lockley, M;
McCormack, M;
Mould, T;
(2019)
Mainstreamed genetic testing for women with ovarian cancer: first-year experience.
Journal of Medical Genetics
, 56
(3)
pp. 195-198.
10.1136/jmedgenet-2017-105140.
|
|
Ray-Coquard, I;
Trama, A;
Seckl, MJ;
Fotopoulou, C;
Pautier, P;
Pignata, S;
Kristensen, G;
... RARECARENet Working Group, .; + view all
(2019)
Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting.
European Journal of Surgical Oncology
, 45
(1)
pp. 67-74.
10.1016/j.ejso.2017.09.025.
|
|
Rosenthal, R;
Cadieux, EL;
Salgado, R;
Bakir, MA;
Moore, DA;
Hiley, CT;
Lund, T;
... TRACERx consortium; + view all
(2019)
Neoantigen-directed immune escape in lung cancer evolution.
Nature
10.1038/s41586-019-1032-7.
(In press).
|
|
Rule, S;
Cook, G;
Russell, NH;
Hunter, A;
Robinson, S;
Morley, N;
Sureda, A;
... Peggs, KS; + view all
(2019)
Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma.
British Journal of Haematology
, 184
(6)
pp. 999-1005.
10.1111/bjh.15723.
|
|
Spiro, SG;
Shah, PL;
Rintoul, RC;
George, J;
Janes, S;
Callister, M;
Novelli, M;
... Hackshaw, A; + view all
(2019)
Sequential screening for lung cancer in a high-risk group: randomised controlled trial.
European Respiratory Journal
, 54
(4)
, Article 1900581. 10.1183/13993003.00581-2019.
|
|
Tan, WS;
Teo, CH;
Chan, D;
Heinrich, M;
Feber, A;
Sarpong, R;
Allan, J;
... DETECT II trial collaborators; + view all
(2019)
Mix methods approach to explore patients' perspectives on the acceptability of a urinary biomarker test in replacement of cystoscopy in bladder cancer surveillance.
BJU International
, 124
(3)
pp. 408-417.
10.1111/bju.14690.
|
|
|
Townsend, W;
Leong, S;
Hoskin, P;
Diez, P;
Patrick, P;
Linch, D;
Wong, W-L;
... Ardeshna, K; + view all
(2019)
Treatment of classical Hodgkin lymphoma in young adults aged 18-30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012).
British Journal of Haematology
10.1111/bjh.16296.
(In press).
|
|
|
Urkmez, E;
Andac-Jones, E;
Cibula, D;
Querleu, D;
Halaska, MJ;
Driak, D;
Sehouli, J;
... Gultekin, M; + view all
(2019)
Perceptions, expectations, and experiences of gynecological cancer patients: a pan-European ESGO-ENGAGe survey.
International Journal of Gynecological Cancer
, 29
(9)
pp. 1425-1430.
10.1136/ijgc-2019-000567.
|
|
|
Webster, AK;
Hung, A;
Moore, BT;
Guzman, R;
Jordan, JM;
Kaplan, REW;
Hibshman, JD;
... Baugh, LR; + view all
(2019)
Population Selection and Sequencing of Caenorhabditis elegans Wild Isolates Identifies a Region on Chromosome III Affecting Starvation Resistance.
G3
, 9
(10)
pp. 3477-3488.
10.1534/g3.119.400617.
|
|
|
Wheeler, G;
Pallmann, P;
Wan, F;
Mander, A;
Yap, C;
Clive, S;
Hampson, L;
(2019)
Designing and evaluating dose-escalation studies made easy: the MoDEsT web app.
Clinical Trials
10.1177/1740774519890146.
(In press).
|
|
|
Wheeler, GM;
Mander, A;
Bedding, A;
Brock, K;
Cornelius, V;
Grieve, A;
Jaki, T;
... Bond, S; + view all
(2019)
How to design a dose-finding study using the Continual Reassessment Method.
BMC Medical Research Methodology
, 19
, Article 18. 10.1186/s12874-018-0638-z.
|
|
|
Wheeler, GM;
Sweeting, M;
Mander, A;
(2019)
A Bayesian model‐free approach to combination therapy phase I trials using censored time‐to‐toxicity data.
Journal of the Royal Statistical Society: Series C (Applied Statistics)
, 68
(2)
pp. 309-329.
10.1111/rssc.12323.
|
Proceedings paper
|
Raza, SEA;
AbdulJabbar, K;
Jamal-Hanjani, M;
Veeriah, S;
Le Quesne, J;
Swanton, C;
Yuan, Y;
(2019)
Deconvolving Convolutional Neural Network for Cell Detection.
In:
2019 IEEE 16th International Symposium on Biomedical Imaging (ISBI 2019).
(pp. pp. 891-894).
IEEE: Venice, Italy,.
|
|
Thesis
|
Hainsworth, Emma Georgina;
(2019)
HIV positive and treated for cancer: the social context and lived experiences of dual diagnosis and its treatment.
Doctoral thesis (Ph.D), UCL (University College London).
|
